AbCellera Biologics Inc. ABCL Analyst Ratings

5 ratings from Wall Street analysts · consensus as of Aug 25, 2026

Analyst Ratings
Strong Buy Avg target $17 showing 5 ratings
Consensus is Strong Buy with a $17.13 average target across 9 analysts (S&P Global and TipRanks via stockanalysis.com, as of 18 August 2026), on a range of $9 to $30 and a $15 median. The spread is the point: the two targets set the day of the ABCL635 Phase 2 readout went to $25 and $30, while the low end has not been revised since before it. Rows below are the most recent sourced analyst actions. Consensus as of Aug 25, 2026
ABCL
Maintained
2026-08-18
BMO Capital
RatingBuy
From
Target$15
From
Reiterated
2026-08-10
JonesTrading
RatingBuy
From
Target$25
From$13
Reiterated
2026-08-10
Truist Financial
RatingBuy
From
Target$30
From$12
Maintained
2026-08-07
Piper Sandler
RatingBuy
From
Target$12
From
Reiterated
2026-08-06
Cantor Fitzgerald
RatingBuy
From
Target$12
From$11